JPS5925365A - ダイノルフインアミド類似物 - Google Patents

ダイノルフインアミド類似物

Info

Publication number
JPS5925365A
JPS5925365A JP58101844A JP10184483A JPS5925365A JP S5925365 A JPS5925365 A JP S5925365A JP 58101844 A JP58101844 A JP 58101844A JP 10184483 A JP10184483 A JP 10184483A JP S5925365 A JPS5925365 A JP S5925365A
Authority
JP
Japan
Prior art keywords
dynorphin
narcotic
morphine
dynorphinamide
analgesic
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP58101844A
Other languages
English (en)
Japanese (ja)
Other versions
JPH0427995B2 (enExample
Inventor
ナンシ−・エム・リ−
ホラス・エイチ・ロウ
ジヨ−−カング・チヤング
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of California
University of California Berkeley
Original Assignee
University of California
University of California Berkeley
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of California, University of California Berkeley filed Critical University of California
Publication of JPS5925365A publication Critical patent/JPS5925365A/ja
Publication of JPH0427995B2 publication Critical patent/JPH0427995B2/ja
Granted legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/665—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans derived from pro-opiomelanocortin, pro-enkephalin or pro-dynorphin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Biomedical Technology (AREA)
  • Immunology (AREA)
  • Neurology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Neurosurgery (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pain & Pain Management (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Polyamides (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)
JP58101844A 1982-06-10 1983-06-09 ダイノルフインアミド類似物 Granted JPS5925365A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US06/387,005 US4462941A (en) 1982-06-10 1982-06-10 Dynorphin amide analogs
US387005 1982-06-16

Publications (2)

Publication Number Publication Date
JPS5925365A true JPS5925365A (ja) 1984-02-09
JPH0427995B2 JPH0427995B2 (enExample) 1992-05-13

Family

ID=23528034

Family Applications (1)

Application Number Title Priority Date Filing Date
JP58101844A Granted JPS5925365A (ja) 1982-06-10 1983-06-09 ダイノルフインアミド類似物

Country Status (15)

Country Link
US (1) US4462941A (enExample)
EP (1) EP0096592B1 (enExample)
JP (1) JPS5925365A (enExample)
KR (1) KR840005080A (enExample)
AT (1) ATE22449T1 (enExample)
AU (1) AU1448983A (enExample)
CA (1) CA1241645A (enExample)
DE (1) DE3366428D1 (enExample)
DK (1) DK262683A (enExample)
FI (1) FI832095L (enExample)
IL (1) IL68825A0 (enExample)
IS (1) IS2812A7 (enExample)
NO (1) NO832107L (enExample)
PT (1) PT76860B (enExample)
ZA (1) ZA834189B (enExample)

Families Citing this family (84)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS59141547A (ja) * 1983-02-01 1984-08-14 Eisai Co Ltd 鎮痛作用を有する新規ペプタイドおよび製法
US4481191A (en) * 1983-03-30 1984-11-06 The Regents Of The University Of California Method for controlling blood pressure
US5242798A (en) * 1983-07-21 1993-09-07 Scripps Clinic And Research Foundation Synthetic polypeptides corresponding to portions of proteinoids translated from brain-specific mRNAs, receptors, methods and diagnostics using the same
US4900811A (en) * 1983-07-21 1990-02-13 Scripps Clinic And Research Foundation Synthetic polypeptides corresponding to portions of proteinoids translated from brain-specific mRNAs, receptors, methods and diagnostics using the same
EP0147194B1 (en) * 1983-12-22 1989-07-19 Yoshio Hosobuchi Compositions for treating cerebral ischemia
JPH0680079B2 (ja) * 1984-11-09 1994-10-12 エーザイ株式会社 ポリペプチド
US5017689A (en) * 1989-07-06 1991-05-21 Arizona Technology Development Corporation Dynorphin analogs specific for kappa opioid receptors
US5807827A (en) * 1992-06-12 1998-09-15 Des-Tyr Dynorphin Partnership Des-Tyr dynorphin analogues
US5817628A (en) * 1992-12-02 1998-10-06 The Rockefeller University Dynorphin a suppression of natural killer cell activity
US5482930A (en) * 1993-06-09 1996-01-09 The Regents Of The University Of California Anti-inflammatory composition and method with des-Tyr dynorphin and analogues
US6184208B1 (en) 1994-06-29 2001-02-06 Immunotech Developments Inc. Peptide, a method for its preparation and a pharmaceutical composition containing the peptide
EP0788371A1 (en) * 1994-08-26 1997-08-13 LEE, Nancy M. Analgesic method with dynorphin analogues truncated at the n-terminus
US7220737B1 (en) 1997-09-04 2007-05-22 Novoneuron, Inc Noribogaine in the treatment of pain and drug addiction
EP1009407B1 (en) 1997-09-04 2004-04-28 Novoneuron, Inc. Noribogaine in the treatment of pain and drug addiction
US6437092B1 (en) 1998-11-06 2002-08-20 Conjuchem, Inc. Conjugates of opioids and endogenous carriers
US6605648B1 (en) * 1999-04-06 2003-08-12 Phillips Plastics Corporation Sinterable structures and method
US6514500B1 (en) * 1999-10-15 2003-02-04 Conjuchem, Inc. Long lasting synthetic glucagon like peptide {GLP-!}
US20090175821A1 (en) * 1999-05-17 2009-07-09 Bridon Dominique P Modified therapeutic peptides with extended half-lives in vivo
US7601691B2 (en) 1999-05-17 2009-10-13 Conjuchem Biotechnologies Inc. Anti-obesity agents
US6849714B1 (en) 1999-05-17 2005-02-01 Conjuchem, Inc. Protection of endogenous therapeutic peptides from peptidase activity through conjugation to blood components
US6887470B1 (en) 1999-09-10 2005-05-03 Conjuchem, Inc. Protection of endogenous therapeutic peptides from peptidase activity through conjugation to blood components
US20040266673A1 (en) * 2002-07-31 2004-12-30 Peter Bakis Long lasting natriuretic peptide derivatives
US6329336B1 (en) * 1999-05-17 2001-12-11 Conjuchem, Inc. Long lasting insulinotropic peptides
EP2100901A1 (en) 1999-05-17 2009-09-16 ConjuChem Biotechnologies Inc. Modified Insulin and conjugates thereof
US6706892B1 (en) * 1999-09-07 2004-03-16 Conjuchem, Inc. Pulmonary delivery for bioconjugation
EP1221975B1 (en) * 1999-10-04 2006-12-06 Nektar Therapeutics Al, Corporation Polymer stabilized neuropeptides
CN101696240A (zh) * 2001-02-02 2010-04-21 康久化学生物技术公司 长效生长激素释放因子衍生物
WO2002066511A2 (en) * 2001-02-16 2002-08-29 Conjuchem Inc. Long lasting glucagon-like peptide 2 (glp-2) for the treatment of gastrointestinal diseases and disorders
US7776314B2 (en) 2002-06-17 2010-08-17 Grunenthal Gmbh Abuse-proofed dosage system
US20070048228A1 (en) 2003-08-06 2007-03-01 Elisabeth Arkenau-Maric Abuse-proofed dosage form
DE10336400A1 (de) 2003-08-06 2005-03-24 Grünenthal GmbH Gegen Missbrauch gesicherte Darreichungsform
DE102005005446A1 (de) 2005-02-04 2006-08-10 Grünenthal GmbH Bruchfeste Darreichungsformen mit retardierter Freisetzung
US8075872B2 (en) 2003-08-06 2011-12-13 Gruenenthal Gmbh Abuse-proofed dosage form
DE102004032051A1 (de) * 2004-07-01 2006-01-19 Grünenthal GmbH Verfahren zur Herstellung einer gegen Missbrauch gesicherten, festen Darreichungsform
DE10361596A1 (de) 2003-12-24 2005-09-29 Grünenthal GmbH Verfahren zur Herstellung einer gegen Missbrauch gesicherten Darreichungsform
PT1745078E (pt) * 2004-04-23 2009-09-17 Conjuchem Biotechnologies Inc Método para a purificação de conjugados de albumina
DE102004032049A1 (de) 2004-07-01 2006-01-19 Grünenthal GmbH Gegen Missbrauch gesicherte, orale Darreichungsform
CA2580694A1 (en) * 2004-09-23 2006-03-30 Alexander Michalow Methods for regulating neurotransmitter systems by inducing counteradaptations
US20080045610A1 (en) * 2004-09-23 2008-02-21 Alexander Michalow Methods for regulating neurotransmitter systems by inducing counteradaptations
DE102005005449A1 (de) 2005-02-04 2006-08-10 Grünenthal GmbH Verfahren zur Herstellung einer gegen Missbrauch gesicherten Darreichungsform
WO2007053946A1 (en) * 2005-11-09 2007-05-18 Conjuchem Biotechnologies Inc. Method of treating diabetes and/or obesity with reduced nausea side effects using an insulinotropic peptide conjugated to albumin
AU2006329215A1 (en) * 2005-12-22 2007-06-28 Conjuchem Biotechnologies Inc. Process for the production of preformed conjugates of albumin and a therapeutic agent
WO2008077194A1 (en) * 2006-12-22 2008-07-03 Xenome Ltd Receptor agonists
US20090099074A1 (en) * 2007-01-10 2009-04-16 Conjuchem Biotechnologies Inc. Modulating food intake
DE102007011485A1 (de) 2007-03-07 2008-09-11 Grünenthal GmbH Darreichungsform mit erschwertem Missbrauch
EP2231191A2 (en) * 2007-12-11 2010-09-29 ConjuChem Biotechnologies Inc. Formulation of insulinotropic peptide conjugates
US8383152B2 (en) 2008-01-25 2013-02-26 Gruenenthal Gmbh Pharmaceutical dosage form
TWI524904B (zh) 2008-05-09 2016-03-11 歌林達股份有限公司 製備醫藥用固體劑型，尤指錠劑之方法，及製備固體劑型，尤指錠劑之前驅物之方法
NZ596668A (en) 2009-07-22 2013-09-27 Gruenenthal Chemie Oxidation-stabilized tamper-resistant dosage form
JP5667183B2 (ja) 2009-07-22 2015-02-12 グリュネンタール・ゲゼルシャフト・ミト・ベシュレンクテル・ハフツング 加熱溶融押出成型した制御放出性投与剤型
EP2531176B1 (en) 2010-02-03 2016-09-07 Grünenthal GmbH Preparation of a powdery pharmaceutical composition by means of an extruder
US8362007B1 (en) 2010-05-11 2013-01-29 Demerx, Inc. Substituted noribogaine
US9394294B2 (en) 2010-05-11 2016-07-19 Demerx, Inc. Methods and compositions for preparing and purifying noribogaine
US8765737B1 (en) 2010-05-11 2014-07-01 Demerx, Inc. Methods and compositions for preparing and purifying noribogaine
US8741891B1 (en) 2010-06-22 2014-06-03 Demerx, Inc. N-substituted noribogaine prodrugs
US9586954B2 (en) 2010-06-22 2017-03-07 Demerx, Inc. N-substituted noribogaine prodrugs
US8802832B2 (en) 2010-06-22 2014-08-12 Demerx, Inc. Compositions comprising noribogaine and an excipient to facilitate transport across the blood brain barrier
US8637648B1 (en) 2010-06-22 2014-01-28 Demerx, Inc. Compositions comprising noribogaine and an excipient to facilitate transport across the blood brain barrier
UA111065C2 (uk) 2010-07-23 2016-03-25 Демеркс, Інк. Композиції норибогаїну
MX2013002293A (es) 2010-09-02 2013-05-09 Gruenenthal Gmbh Forma de dosificacion resistente a alteracion que comprende un polimero anionico.
ES2486791T3 (es) 2010-09-02 2014-08-19 Grünenthal GmbH Forma de dosificación resistente a la manipulación que comprende una sal inorgánica
EP2481740B1 (en) 2011-01-26 2015-11-04 DemeRx, Inc. Methods and compositions for preparing noribogaine from voacangine
EA201400172A1 (ru) 2011-07-29 2014-06-30 Грюненталь Гмбх Устойчивая к разрушению таблетка, которая обеспечивает немедленное высвобождение лекарственного средства
PE20141650A1 (es) 2011-07-29 2014-11-22 Gruenenthal Chemie Tableta a prueba de alteracion que proporciona liberacion inmediata del farmaco
US9617274B1 (en) 2011-08-26 2017-04-11 Demerx, Inc. Synthetic noribogaine
JP2015500833A (ja) 2011-12-09 2015-01-08 デメレックス， インコーポレイテッド ノルイボガインのリン酸エステル
US9150584B2 (en) 2012-01-25 2015-10-06 Demerx, Inc. Indole and benzofuran fused isoquinuclidene derivatives and processes for preparing them
WO2013112673A1 (en) 2012-01-25 2013-08-01 Demerx, Inc. Synthetic voacangine
WO2013127831A1 (en) 2012-02-28 2013-09-06 Grünenthal GmbH Tamper-resistant dosage form comprising pharmacologically active compound and anionic polymer
ES2692944T3 (es) 2012-04-18 2018-12-05 Grünenthal GmbH Forma de dosificación farmacéutica resistente a la manipulación y resistente a la descarga rápida de la dosis
US10064945B2 (en) 2012-05-11 2018-09-04 Gruenenthal Gmbh Thermoformed, tamper-resistant pharmaceutical dosage form containing zinc
US9045481B2 (en) 2012-12-20 2015-06-02 Demerx, Inc. Substituted noribogaine
US8940728B2 (en) 2012-12-20 2015-01-27 Demerx, Inc. Substituted noribogaine
EP2934541A4 (en) 2012-12-20 2016-08-03 Demerx Inc NORIBOGAINE SUBSTITUTE
US10428115B2 (en) 2013-05-24 2019-10-01 Arizona Board Of Regents On Behalf Of The University Of Arizona Dynorphin A analogs with bradykinin receptors specificity for modulation of neuropathic pain
BR112015026549A2 (pt) 2013-05-29 2017-07-25 Gruenenthal Gmbh forma de dosagem à prova de violação contendo uma ou mais partículas
US9737490B2 (en) 2013-05-29 2017-08-22 Grünenthal GmbH Tamper resistant dosage form with bimodal release profile
AU2014289187B2 (en) 2013-07-12 2019-07-11 Grunenthal Gmbh Tamper-resistant dosage form containing ethylene-vinyl acetate polymer
AU2014356581C1 (en) 2013-11-26 2020-05-28 Grunenthal Gmbh Preparation of a powdery pharmaceutical composition by means of cryo-milling
MX2016014738A (es) 2014-05-12 2017-03-06 Gruenenthal Gmbh Formulacion en capsula de liberacion inmediata resistente a alteraciones que comprende tapentadol.
CN106456550A (zh) 2014-05-26 2017-02-22 格吕伦塔尔有限公司 避免乙醇剂量倾泻的多颗粒
US9550789B2 (en) 2014-06-18 2017-01-24 Demerx, Inc. Halogenated indole and benzofuran derivatives of isoquinuclidene and processes for preparing them
BR112017021475A2 (pt) 2015-04-24 2018-07-10 Gruenenthal Gmbh forma de dosagem resistente à adulteração (tamper) com liberação imediata e resistência contra extração de solvente
CA2998259A1 (en) 2015-09-10 2017-03-16 Grunenthal Gmbh Protecting oral overdose with abuse deterrent immediate release formulations

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5572153A (en) * 1978-11-26 1980-05-30 Shionogi & Co Ltd Undecapeptide

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4396606A (en) * 1979-11-05 1983-08-02 Addiction Research Foundation Novel polypeptide analgesics
US4361553A (en) * 1981-05-18 1982-11-30 Regents Of The University Of California Therapeutic uses of dynorphin
JPS5815946A (ja) 1981-07-21 1983-01-29 Eisai Co Ltd 新規ヘプタデカペプタイド

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5572153A (en) * 1978-11-26 1980-05-30 Shionogi & Co Ltd Undecapeptide

Also Published As

Publication number Publication date
EP0096592B1 (en) 1986-09-24
FI832095A0 (fi) 1983-06-10
PT76860A (en) 1983-07-01
FI832095A7 (fi) 1983-12-11
IL68825A0 (en) 1983-09-30
PT76860B (en) 1986-01-27
US4462941A (en) 1984-07-31
ATE22449T1 (de) 1986-10-15
DK262683D0 (da) 1983-06-09
DE3366428D1 (en) 1986-10-30
ZA834189B (en) 1984-02-29
FI832095L (fi) 1983-12-11
IS2812A7 (is) 1983-10-07
EP0096592A1 (en) 1983-12-21
AU1448983A (en) 1983-12-15
KR840005080A (ko) 1984-11-03
JPH0427995B2 (enExample) 1992-05-13
CA1241645A (en) 1988-09-06
NO832107L (no) 1983-12-12
DK262683A (da) 1983-12-11

Similar Documents

Publication Publication Date Title
JPS5925365A (ja) ダイノルフインアミド類似物
KR102068370B1 (ko) 심부전의 치료를 위한 합성 아펠린 모방체
TW580502B (en) Kappa receptor opioid peptides
CZ281630B6 (cs) Analogy des-tyr dynorfinu
US7396814B2 (en) Metallopeptide compositions for treatment of sexual dysfunction
Kleczkowska et al. Hybrid opioid/non-opioid ligands in pain research
CN101454338A (zh) κ阿片样受体肽的N-氧化物
PL181092B1 (pl) Związek o obwodowych efektach znieczulających i kompozycja farmaceutyczna o obwodowej aktywności przeciwbólowej
Burcher et al. Concepts in characterization of tachykinin receptors
Aldrich et al. Peptide kappa opioid receptor ligands and their potential for drug development
EP0029300B1 (en) Polypeptides, antisera containing them and methods of their use
US4481191A (en) Method for controlling blood pressure
Adams et al. The role of endogenous peptides in the action of opioid analgesics
Fichna et al. Characterization of antinociceptive activity of novel endomorphin-2 and morphiceptin analogs modified in the third position
KR910009730A (ko) 펩티드
JPH0770178A (ja) 胃腸運動刺激活性を有するモチリン類似ポリペプチド
US11141452B2 (en) Bifunctional compounds for relief of pain comprising an opioid receptor agonist moiety and a NK1 receptor antagonist moiety and methods for treating pain
US5061691A (en) Enkephalin analogs
Biondi et al. Opioid peptides: synthesis and biological activity of new endomorphin analogues
Costante et al. Potent biphalin analogs with µ/δ mixed opioid activity: in vivo and in vitro biological evaluation
WO2019170919A1 (en) Hybrid mu opioid receptor and neuropeptide ff receptor binding molecules, their methods of preparation and applications in therapeutic treatment
Lipkowski et al. Opioid-Substance P chimeric peptides
Snyder Synthesis and opioid activity of dynorphin a analogues
Gisemba Design and synthesis of cyclic analogs of the kappa opioid receptor antagonist arodyn
Rew Synthesis and biological activities of heteroatom-bridged cyclic enkephalin analogs